{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:53:41Z","timestamp":1792072421294,"version":"4.4.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,9,18]],"date-time":"2012-09-18T00:00:00Z","timestamp":1347926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1038\/nrneph.2012.195","type":"journal-article","created":{"date-parts":[[2012,9,18]],"date-time":"2012-09-18T05:22:58Z","timestamp":1347945778000},"page":"622-633","source":"Crossref","is-referenced-by-count":325,"title":["STEC-HUS, atypical HUS and TTP are all diseases of complement activation"],"prefix":"10.1038","volume":"8","author":[{"given":"Marina","family":"Noris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Mescia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,18]]},"reference":[{"key":"BFnrneph2012195_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1046\/j.1523-1755.2001.060003831.x","volume":"60","author":"P Ruggenenti","year":"2001","unstructured":"Ruggenenti, P., Noris, M. & Remuzzi, G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 60, 831\u2013846 (2001).","journal-title":"Kidney Int."},{"key":"BFnrneph2012195_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1182\/blood-2001-12-0166","volume":"100","author":"G Remuzzi","year":"2002","unstructured":"Remuzzi, G. et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 100, 778\u2013785 (2002).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/ki.1987.206","volume":"32","author":"G Remuzzi","year":"1987","unstructured":"Remuzzi, G. HUS and TTP: variable expression of a single entity. Kidney Int. 32, 292\u2013308 (1987).","journal-title":"Kidney Int."},{"key":"BFnrneph2012195_CR4","first-page":"1073","volume":"365","author":"PI Tarr","year":"2005","unstructured":"Tarr, P. I., Gordon, C. A. & Chandler, W. L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365, 1073\u20131086 (2005).","journal-title":"Lancet"},{"key":"BFnrneph2012195_CR5","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris, M. & Remuzzi, G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361, 1676\u20131687 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012195_CR6","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00467-010-1555-5","volume":"25","author":"D Kavanagh","year":"2010","unstructured":"Kavanagh, D. & Goodship, T. Genetics and complement in atypical HUS. Pediatr. Nephrol. 25, 2431\u20132442 (2010).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012195_CR7","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","volume":"339","author":"M Furlan","year":"1998","unstructured":"Furlan, M. et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N. Engl. J. Med. 339, 1578\u20131584 (1998).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012195_CR8","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","volume":"339","author":"HM Tsai","year":"1998","unstructured":"Tsai, H. M. & Lian, E. C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N. Engl. J. Med. 339, 1585\u20131594 (1998).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012195_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12185-009-0476-1","volume":"91","author":"HM Tsai","year":"2010","unstructured":"Tsai, H. M. Pathophysiology of thrombotic thrombocytopenic purpura. Int. J. Hematol. 91, 1\u201319 (2010).","journal-title":"Int. J. Hematol."},{"key":"BFnrneph2012195_CR10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1046\/j.1538-7836.2003.00169.x","volume":"1","author":"HM Tsai","year":"2003","unstructured":"Tsai, H. M. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J. Thromb. Haemost. 1, 625\u2013631 (2003).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrneph2012195_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00441-010-1034-0","volume":"343","author":"JV Sarma","year":"2011","unstructured":"Sarma, J. V. & Ward, P. A. The complement system. Cell Tissue Res. 343, 227\u2013235 (2011).","journal-title":"Cell Tissue Res."},{"key":"BFnrneph2012195_CR12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785\u2013797 (2010).","journal-title":"Nat. Immunol."},{"key":"BFnrneph2012195_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4049\/jimmunol.1100491","volume":"187","author":"M Morigi","year":"2011","unstructured":"Morigi, M. et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J. Immunol. 187, 172\u2013180 (2011).","journal-title":"J. Immunol."},{"key":"BFnrneph2012195_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1055\/s-0038-1655974","volume":"77","author":"K Ikeda","year":"1997","unstructured":"Ikeda, K. et al. C5a induces tissue factor activity on endothelial cells. Thromb. Haemost. 77, 394\u2013398 (1997).","journal-title":"Thromb. Haemost."},{"key":"BFnrneph2012195_CR15","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1084\/jem.185.9.1619","volume":"185","author":"F Tedesco","year":"1997","unstructured":"Tedesco, F. et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J. Exp. Med. 185, 1619\u20131627 (1997).","journal-title":"J. Exp. Med."},{"key":"BFnrneph2012195_CR16","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1084\/jem.171.4.1363","volume":"171","author":"JL Platt","year":"1990","unstructured":"Platt, J. L. et al. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J. Exp. Med. 171, 1363\u20131368 (1990).","journal-title":"J. Exp. Med."},{"key":"BFnrneph2012195_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1084\/jem.181.1.21","volume":"181","author":"S Saadi","year":"1995","unstructured":"Saadi, S. & Platt, J. L. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J. Exp. Med. 181, 21\u201331 (1995).","journal-title":"J. Exp. Med."},{"key":"BFnrneph2012195_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1023\/A:1022362413939","volume":"22","author":"KS Kilgore","year":"1998","unstructured":"Kilgore, K. S., Ward, P. A. & Warren, J. S. Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: the roles of P-selectin and platelet activating factor. Inflammation 22, 583\u2013598 (1998).","journal-title":"Inflammation"},{"key":"BFnrneph2012195_CR19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0002-9440(10)63173-2","volume":"164","author":"EA Albrecht","year":"2004","unstructured":"Albrecht, E. A. et al. C5a-induced gene expression in human umbilical vein endothelial cells. Am. J. Pathol. 164, 849\u2013859 (2004).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph2012195_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1182\/blood.V99.1.185","volume":"99","author":"A Dobrina","year":"2002","unstructured":"Dobrina, A. et al. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood 99, 185\u2013192 (2002).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1385\/IR:24:2:191","volume":"24","author":"F Niculescu","year":"2001","unstructured":"Niculescu, F. & Rus, H. Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol. Res. 24, 191\u2013199 (2001).","journal-title":"Immunol. Res."},{"key":"BFnrneph2012195_CR22","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1016\/j.molimm.2009.04.027","volume":"46","author":"A Klos","year":"2009","unstructured":"Klos, A. et al. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46, 2753\u20132766 (2009).","journal-title":"Mol. Immunol."},{"key":"BFnrneph2012195_CR23","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1084\/jem.147.6.1713","volume":"147","author":"MJ Polley","year":"1978","unstructured":"Polley, M. J. & Nachman, R. The human complement system in thrombin-mediated platelet function. J. Exp. Med. 147, 1713\u20131726 (1978).","journal-title":"J. Exp. Med."},{"key":"BFnrneph2012195_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1084\/jem.158.2.603","volume":"158","author":"MJ Polley","year":"1983","unstructured":"Polley, M. J. & Nachman, R. L. Human platelet activation by C3a and C3a des-arg. J. Exp. Med. 158, 603\u2013615 (1983).","journal-title":"J. Exp. Med."},{"key":"BFnrneph2012195_CR25","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1016\/S0021-9258(17)39556-X","volume":"260","author":"T Wiedmer","year":"1985","unstructured":"Wiedmer, T. & Sims, P. J. Effect of complement proteins C5b-9 on blood platelets. Evidence for reversible depolarization of membrane potential. J. Biol. Chem. 260, 8014\u20138019 (1985).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph2012195_CR26","doi-asserted-by":"crossref","first-page":"11907","DOI":"10.1016\/S0021-9258(18)37872-4","volume":"263","author":"B Ando","year":"1988","unstructured":"Ando, B., Wiedmer, T., Hamilton, K. K. & Sims, P. J. Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa. J. Biol. Chem. 263, 11907\u201311914 (1988).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph2012195_CR27","doi-asserted-by":"crossref","first-page":"14587","DOI":"10.1016\/S0021-9258(18)66911-X","volume":"261","author":"T Wiedmer","year":"1986","unstructured":"Wiedmer, T., Esmon, C. T. & Sims, P. J. On the mechanism by which complement proteins C5b-9 increase platelet prothrombinase activity. J. Biol. Chem. 261, 14587\u201314592 (1986).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph2012195_CR28","doi-asserted-by":"crossref","first-page":"18205","DOI":"10.1016\/S0021-9258(19)81346-7","volume":"263","author":"PJ Sims","year":"1988","unstructured":"Sims, P. J., Faioni, E. M., Wiedmer, T. & Shattil, S. J. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J. Biol. Chem. 263, 18205\u201318212 (1988).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph2012195_CR29","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1182\/blood-2007-08-106153","volume":"111","author":"AL St\u00e5hl","year":"2008","unstructured":"St\u00e5hl, A. L. et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 111, 5307\u20135315 (2008).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1538-7836.2009.03334.x","volume":"7","author":"FC Gushiken","year":"2009","unstructured":"Gushiken, F. C., Han, H., Li, J., Rumbaut, R. E. & Afshar-Kharghan, V. Abnormal platelet function in C3-deficient mice. J. Thromb. Haemost. 7, 865\u2013870 (2009).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrneph2012195_CR31","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.4049\/jimmunol.154.9.4734","volume":"154","author":"AK H\u00f8g\u00e5sen","year":"1995","unstructured":"H\u00f8g\u00e5sen, A. K., W\u00fcrzner, R., Abrahamsen, T. G. & Dierich, M. P. Human polymorphonuclear leukocytes store large amounts of terminal complement components C7 and C6, which may be released on stimulation. J. Immunol. 154, 4734\u20134740 (1995).","journal-title":"J. Immunol."},{"key":"BFnrneph2012195_CR32","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4049\/jimmunol.149.4.1348","volume":"149","author":"M Botto","year":"1992","unstructured":"Botto, M., Lissandrini, D., Sorio, C. & Walport, M. J. Biosynthesis and secretion of complement component (C3) by activated human polymorphonuclear leukocytes. J. Immunol. 149, 1348\u20131355 (1992).","journal-title":"J. Immunol."},{"key":"BFnrneph2012195_CR33","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S0171-2985(96)80050-7","volume":"195","author":"W Vogt","year":"1996","unstructured":"Vogt, W. Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes. Immunobiology 195, 334\u2013346 (1996).","journal-title":"Immunobiology"},{"key":"BFnrneph2012195_CR34","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1182\/blood-2010-05-283564","volume":"117","author":"L Camous","year":"2011","unstructured":"Camous, L. et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117, 1340\u20131349 (2011).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR35","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.molimm.2010.05.009","volume":"47","author":"EI Peerschke","year":"2010","unstructured":"Peerschke, E. I., Yin, W. & Ghebrehiwet, B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol. Immunol. 47, 2170\u20132175 (2010).","journal-title":"Mol. Immunol."},{"key":"BFnrneph2012195_CR36","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","volume":"185","author":"U Amara","year":"2010","unstructured":"Amara, U. et al. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 185, 5628\u20135636 (2010).","journal-title":"J. Immunol."},{"key":"BFnrneph2012195_CR37","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1106483","volume":"365","author":"C Frank","year":"2011","unstructured":"Frank, C. et al. for the HUS Investigation Team. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N. Engl. J. Med. 365, 1771\u20131780 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012195_CR38","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1106920","volume":"365","author":"DA Rasko","year":"2011","unstructured":"Rasko, D. A. et al. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N. Engl. J. Med. 365, 709\u2013717 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012195_CR39","doi-asserted-by":"crossref","first-page":"15484","DOI":"10.1016\/S0021-9258(18)82282-7","volume":"268","author":"TG Obrig","year":"1993","unstructured":"Obrig, T. G. et al. Endothelial heterogeneity in Shiga toxin receptors and responses. J. Biol. Chem. 268, 15484\u201315488 (1993).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph2012195_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrmicro2279","volume":"8","author":"L Johannes","year":"2010","unstructured":"Johannes, L. & R\u00f6mer, W. Shiga toxins\u2014from cell biology to biomedical applications. Nat. Rev. Microbiol. 8, 105\u2013116 (2010).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFnrneph2012195_CR41","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1046\/j.1523-1755.2002.00503.x","volume":"62","author":"C Zoja","year":"2002","unstructured":"Zoja, C. et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-\u03baB dependent up-regulation of IL-8 and MCP-1. Kidney Int. 62, 846\u2013856 (2002).","journal-title":"Kidney Int."},{"key":"BFnrneph2012195_CR42","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1172\/JCI57313","volume":"122","author":"TN Petruzziello-Pellegrini","year":"2012","unstructured":"Petruzziello-Pellegrini, T. N. et al. The CXCR4\/CXCR7\/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J. Clin. Invest. 122, 759\u2013776 (2012).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2012195_CR43","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/blood.V86.12.4553.bloodjournal86124553","volume":"86","author":"M Morigi","year":"1995","unstructured":"Morigi, M. et al. Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. Blood 86, 4553\u20134558 (1995).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR44","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1182\/blood.V98.6.1828","volume":"98","author":"M Morigi","year":"2001","unstructured":"Morigi, M. et al. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 98, 1828\u20131835 (2001).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR45","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.1538-7836.2005.01205.x","volume":"3","author":"E Nestoridi","year":"2005","unstructured":"Nestoridi, E., Tsukurov, O., Kushak, R. I., Ingelfinger, J. R. & Grabowski, E. F. Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome. J. Thromb. Haemost. 3, 752\u2013762 (2005).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrneph2012195_CR46","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1182\/blood.V97.10.3100","volume":"97","author":"D Karpman","year":"2001","unstructured":"Karpman, D. et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 97, 3100\u20133108 (2001).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR47","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood.V88.1.174.174","volume":"88","author":"PA van Setten","year":"1996","unstructured":"van Setten, P. A., Monnens, L. A., Verstraten, R. G., van den Heuvel, L. P. & van Hinsbergh, V. W. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 88, 174\u2013183 (1996).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR48","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S0140-6736(73)92645-7","volume":"2","author":"JS Cameron","year":"1973","unstructured":"Cameron, J. S. & Vick, R. Letter: Plasma-C3 in haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura. Lancet 2, 975 (1973).","journal-title":"Lancet"},{"key":"BFnrneph2012195_CR49","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(73)92782-7","volume":"2","author":"BS Kaplan","year":"1973","unstructured":"Kaplan, B. S., Thomson, P. D. & MacNab, G. M. Letter: Serum-complement levels in haemolytic-uraemic syndrome. Lancet 2, 1505\u20131506 (1973).","journal-title":"Lancet"},{"key":"BFnrneph2012195_CR50","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(74)91463-9","volume":"2","author":"L Monnens","year":"1974","unstructured":"Monnens, L., Hendrickx, G., van Wieringen, P. & van Munster, P. Letter: Serum-complement levels in haemolytic-uraemic syndrome. Lancet 2, 294 (1974).","journal-title":"Lancet"},{"key":"BFnrneph2012195_CR51","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000187063","volume":"62","author":"WL Robson","year":"1992","unstructured":"Robson, W. L., Leung, A. K., Fick, G. H. & McKenna, A. I. Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron 62, 296\u2013299 (1992).","journal-title":"Nephron"},{"key":"BFnrneph2012195_CR52","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMc1100859","volume":"364","author":"AL Lapeyraque","year":"2011","unstructured":"Lapeyraque, A. L. et al. Eculizumab in severe Shiga-toxin-associated HUS. N. Engl. J. Med. 364, 2561\u20132563 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012195_CR53","first-page":"168","volume":"13","author":"L Monnens","year":"1980","unstructured":"Monnens, L., Molenaar, J., Lambert, P. H., Proesmans, W. & van Munster, P. The complement system in hemolytic-uremic syndrome in childhood. Clin. Nephrol. 13, 168\u2013171 (1980).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph2012195_CR54","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.2215\/CJN.02730409","volume":"4","author":"JM Thurman","year":"2009","unstructured":"Thurman, J. M. et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 4, 1920\u20131924 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012195_CR55","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1182\/blood-2010-09-309161","volume":"117","author":"AL St\u00e5hl","year":"2011","unstructured":"St\u00e5hl, A. L., Sartz, L. & Karpman, D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117, 5503\u20135513 (2011).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR56","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1084\/jem.20041497","volume":"201","author":"I Del Conde","year":"2005","unstructured":"Del Conde, I., Cr\u00faz, M. A., Zhang, H., L\u00f3pez, J. A. & Afshar-Kharghan, V. Platelet activation leads to activation and propagation of the complement system. J. Exp. Med. 201, 871\u2013879 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnrneph2012195_CR57","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","volume":"182","author":"D Orth","year":"2009","unstructured":"Orth, D. et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J. Immunol. 182, 6394\u20136400 (2009).","journal-title":"J. Immunol."},{"key":"BFnrneph2012195_CR58","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/infdis\/151.5.775","volume":"151","author":"MA Karmali","year":"1985","unstructured":"Karmali, M. A. et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151, 775\u2013782 (1985).","journal-title":"J. Infect. Dis."},{"key":"BFnrneph2012195_CR59","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/infdis\/166.1.154","volume":"166","author":"A Caprioli","year":"1992","unstructured":"Caprioli, A. et al. Hemolytic-uremic syndrome and Vero cytotoxin-producing Escherichia coli infection in Italy. The HUS Italian Study Group. J. Infect. Dis. 166, 154\u2013158 (1992).","journal-title":"J. Infect. Dis."},{"key":"BFnrneph2012195_CR60","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0140-6736(74)90991-X","volume":"2","author":"W St\u00fchlinger","year":"1974","unstructured":"St\u00fchlinger, W., Kourilsky, O., Kanfer, A. & Sraer, J. D. Letter: Haemolytic-uraemic syndrome: evidence for intravascular C3 activation. Lancet 2, 788\u2013789 (1974).","journal-title":"Lancet"},{"key":"BFnrneph2012195_CR61","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.1981.03310310044021","volume":"245","author":"L Carreras","year":"1981","unstructured":"Carreras, L. et al. Familial hypocomplementemic hemolytic uremic syndrome with HLA-A3,B7 haplotype. JAMA 245, 602\u2013604 (1981).","journal-title":"JAMA"},{"key":"BFnrneph2012195_CR62","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","volume":"53","author":"P Warwicker","year":"1998","unstructured":"Warwicker, P. et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 53, 836\u2013844 (1998).","journal-title":"Kidney Int."},{"key":"BFnrneph2012195_CR63","volume-title":"NCBI Bookshelf","author":"M Noris","year":"2011","unstructured":"Noris, M., Bresin, E., Mele, C., Remuzzi, G. & Caprioli, J. Atypical hemolytic-uremic syndrome. NCBI Bookshelf [online] , (2011)."},{"key":"BFnrneph2012195_CR64","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1136\/jmg.40.9.676","volume":"40","author":"HP Neumann","year":"2003","unstructured":"Neumann, H. P. et al. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J. Med. Genet. 40, 676\u2013681 (2003).","journal-title":"J. Med. Genet."},{"key":"BFnrneph2012195_CR65","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","volume":"108","author":"J Caprioli","year":"2006","unstructured":"Caprioli, J. et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108, 1267\u20131279 (2006).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR66","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1086\/318203","volume":"68","author":"A Richards","year":"2001","unstructured":"Richards, A. et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18\u201320, a domain important for host cell recognition. Am. J. Hum. Genet. 68, 485\u2013490 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrneph2012195_CR67","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","volume":"362","author":"M Noris","year":"2003","unstructured":"Noris, M. et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362, 1542\u20131547 (2003).","journal-title":"Lancet"},{"key":"BFnrneph2012195_CR68","doi-asserted-by":"publisher","first-page":"12966","DOI":"10.1073\/pnas.2135497100","volume":"100","author":"A Richards","year":"2003","unstructured":"Richards, A. et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc. Natl Acad. Sci. USA 100, 12966\u201312971 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph2012195_CR69","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1136\/jmg.2004.019083","volume":"41","author":"V Fremeaux-Bacchi","year":"2004","unstructured":"Fremeaux-Bacchi, V. et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J. Med. Genet. 41, e84 (2004).","journal-title":"J. Med. Genet."},{"key":"BFnrneph2012195_CR70","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1681\/ASN.2005010103","volume":"16","author":"D Kavanagh","year":"2005","unstructured":"Kavanagh, D. et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16, 2150\u20132155 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012195_CR71","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/ki.2009.472","volume":"77","author":"F Bienaime","year":"2010","unstructured":"Bienaime, F. et al. Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. Kidney Int. 77, 339\u2013349 (2010).","journal-title":"Kidney Int."},{"key":"BFnrneph2012195_CR72","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa0810739","volume":"361","author":"M Delvaeye","year":"2009","unstructured":"Delvaeye, M. et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361, 345\u2013357 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012195_CR73","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","volume":"112","author":"V Fr\u00e9meaux-Bacchi","year":"2008","unstructured":"Fr\u00e9meaux-Bacchi, V. et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112, 4948\u20134952 (2008).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR74","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1073\/pnas.0603420103","volume":"104","author":"E Goicoechea de Jorge","year":"2007","unstructured":"Goicoechea de Jorge, E. et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl Acad. Sci. USA 104, 240\u2013245 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph2012195_CR75","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1681\/ASN.2004050380","volume":"16","author":"MA Dragon-Durey","year":"2005","unstructured":"Dragon-Durey, M. A. et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16, 555\u2013563 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012195_CR76","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2010030315","volume":"21","author":"MA Dragon-Durey","year":"2010","unstructured":"Dragon-Durey, M. A. et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J. Am. Soc. Nephrol. 21, 2180\u20132187 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012195_CR77","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.4049\/jimmunol.0804031","volume":"182","author":"VP Ferreira","year":"2009","unstructured":"Ferreira, V. P. et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J. Immunol. 182, 7009\u20137018 (2009).","journal-title":"J. Immunol."},{"key":"BFnrneph2012195_CR78","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1172\/JCI16651","volume":"111","author":"T Manuelian","year":"2003","unstructured":"Manuelian, T. et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. Invest. 111, 1181\u20131190 (2003).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2012195_CR79","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1681\/ASN.2006091069","volume":"18","author":"S Heinen","year":"2007","unstructured":"Heinen, S. et al. Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells. J. Am. Soc. Nephrol. 18, 506\u2013514 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012195_CR80","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/ndt\/gfp388","volume":"25","author":"S Strobel","year":"2010","unstructured":"Strobel, S. et al. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol. Dial. Transplant. 25, 136\u2013144 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012195_CR81","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1182\/blood-2007-02-071472","volume":"110","author":"M J\u00f3zsi","year":"2007","unstructured":"J\u00f3zsi, M. et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 110, 1516\u20131518 (2007).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR82","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1681\/ASN.2005101051","volume":"17","author":"V Fremeaux-Bacchi","year":"2006","unstructured":"Fremeaux-Bacchi, V. et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 17, 2017\u20132025 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012195_CR83","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.molimm.2007.05.004","volume":"45","author":"D Kavanagh","year":"2008","unstructured":"Kavanagh, D. et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol. Immunol. 45, 95\u2013105 (2008).","journal-title":"Mol. Immunol."},{"key":"BFnrneph2012195_CR84","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/blood-2009-01-197640","volume":"114","author":"LT Roumenina","year":"2009","unstructured":"Roumenina, L. T. et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 114, 2837\u20132845 (2009).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1681\/ASN.V102281","volume":"10","author":"M Noris","year":"1999","unstructured":"Noris, M. et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome\/Thrombotic Thrombocytopenic Purpura. J. Am. Soc. Nephrol. 10, 281\u2013293 (1999).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012195_CR86","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1067\/mpd.2001.112649","volume":"138","author":"D Landau","year":"2001","unstructured":"Landau, D. et al. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J. Pediatr. 138, 412\u2013417 (2001).","journal-title":"J. Pediatr."},{"key":"BFnrneph2012195_CR87","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s004670050515","volume":"12","author":"M Ohali","year":"1998","unstructured":"Ohali, M. et al. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr. Nephrol. 12, 619\u2013624 (1998).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012195_CR88","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/BF00866325","volume":"6","author":"J Zachwieja","year":"1992","unstructured":"Zachwieja, J., Strzykala, K., Golda, W. & Maciejewski, J. Familial, recurrent haemolytic-uraemic syndrome with hypocomplementaemia. Pediatr. Nephrol. 6, 221\u2013222 (1992).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012195_CR89","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/sj.ki.5000155","volume":"69","author":"F Vaziri-Sani","year":"2006","unstructured":"Vaziri-Sani, F. et al. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int. 69, 981\u2013988 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2012195_CR90","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.molimm.2011.06.431","volume":"48","author":"A Richards","year":"2011","unstructured":"Richards, A. Glomerular endothelial microvascular heterogeneity and response to cytokines predispose to development of atypical HUS [abstract]. Mol. Immunol. 48, 1732 (2011).","journal-title":"Mol. Immunol."},{"key":"BFnrneph2012195_CR91","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris, M. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 5, 1844\u20131859 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012195_CR92","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","volume":"115","author":"I Moore","year":"2010","unstructured":"Moore, I. et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115, 379\u2013387 (2010).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR93","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.molimm.2005.11.008","volume":"43","author":"J Esparza-Gordillo","year":"2006","unstructured":"Esparza-Gordillo, J. et al. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol. Immunol. 43, 1769\u20131775 (2006).","journal-title":"Mol. Immunol."},{"key":"BFnrneph2012195_CR94","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/hmg\/ddi066","volume":"14","author":"J Esparza-Gordillo","year":"2005","unstructured":"Esparza-Gordillo, J. et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum. Mol. Genet. 14, 703\u2013712 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneph2012195_CR95","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1084\/jem.20070301","volume":"204","author":"MC Pickering","year":"2007","unstructured":"Pickering, M. C. et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J. Exp. Med. 204, 1249\u20131256 (2007).","journal-title":"J. Exp. Med."},{"key":"BFnrneph2012195_CR96","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1681\/ASN.2009070706","volume":"21","author":"F Fakhouri","year":"2010","unstructured":"Fakhouri, F. et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J. Am. Soc. Nephrol. 21, 859\u2013867 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012195_CR97","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.molimm.2011.06.264","volume":"48","author":"M Galbusera","year":"2011","unstructured":"Galbusera, M. et al. In patients with atypical hemolytic uremic syndrome C5 activation causes loss of endothelial thromboresistance [abstract]. Mol. Immunol. 48, 1680 (2011).","journal-title":"Mol. Immunol."},{"key":"BFnrneph2012195_CR98","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood-2007-04-084533","volume":"111","author":"CJ Fang","year":"2008","unstructured":"Fang, C. J. et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 111, 624\u2013632 (2008).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR99","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","volume":"112","author":"JE Sadler","year":"2008","unstructured":"Sadler, J. E. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 112, 11\u201318 (2008).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR100","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1182\/blood-2002-05-1397","volume":"100","author":"B Plaimauer","year":"2002","unstructured":"Plaimauer, B. et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 100, 3626\u20133632 (2002).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR101","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/35097008","volume":"413","author":"GG Levy","year":"2001","unstructured":"Levy, G. G. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413, 488\u2013494 (2001).","journal-title":"Nature"},{"key":"BFnrneph2012195_CR102","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1160\/TH06-05-0236","volume":"96","author":"R Donadelli","year":"2006","unstructured":"Donadelli, R. et al. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb. Haemost. 96, 454\u2013464 (2006).","journal-title":"Thromb. Haemost."},{"key":"BFnrneph2012195_CR103","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","volume":"102","author":"SK Vesely","year":"2003","unstructured":"Vesely, S. K. et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102, 60\u201368 (2003).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR104","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1182\/blood.V98.6.1765","volume":"98","author":"A Veyradier","year":"2001","unstructured":"Veyradier, A., Obert, B., Houllier, A., Meyer, D. & Girma, J. P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98, 1765\u20131772 (2001).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR105","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/ajcp\/67.1.61","volume":"67","author":"DD Weisenburger","year":"1977","unstructured":"Weisenburger, D. D., O'Conner, M. L. & Hart, M. N. Thrombotic thrombocytopenic purpura with C3 vascular deposits: report of a case. Am. J. Clin. Pathol. 67, 61\u201363 (1977).","journal-title":"Am. J. Clin. Pathol."},{"key":"BFnrneph2012195_CR106","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1046\/j.1365-2141.1999.01751.x","volume":"107","author":"JF Wright","year":"1999","unstructured":"Wright, J. F. et al. Characterization of platelet glycoproteins and platelet\/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura. Br. J. Haematol. 107, 546\u2013555 (1999).","journal-title":"Br. J. Haematol."},{"key":"BFnrneph2012195_CR107","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1160\/TH04-07-0450","volume":"93","author":"MP Ruiz-Torres","year":"2005","unstructured":"Ruiz-Torres, M. P. et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb. Haemost. 93, 443\u2013452 (2005).","journal-title":"Thromb. Haemost."},{"key":"BFnrneph2012195_CR108","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1538-7836.2012.04674.x","volume":"10","author":"M R\u00e9ti","year":"2012","unstructured":"R\u00e9ti, M. et al. Complement activation in thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 10, 791\u2013798 (2012).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrneph2012195_CR109","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","volume":"157","author":"J Chapin","year":"2012","unstructured":"Chapin, J., Weksler, B., Magro, C. & Laurence, J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br. J. Haematol. 157, 772\u2013774 (2012).","journal-title":"Br. J. Haematol."},{"key":"BFnrneph2012195_CR110","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nm1419","volume":"12","author":"M Huber-Lang","year":"2006","unstructured":"Huber-Lang, M. et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12, 682\u2013687 (2006).","journal-title":"Nat. Med."},{"key":"BFnrneph2012195_CR111","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1365-2125.2009.03491.x","volume":"68","author":"EA Dubois","year":"2009","unstructured":"Dubois, E. A. & Cohen, A. F. Eculizumab. Br. J. Clin. Pharmacol. 68, 318\u2013319 (2009).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrneph2012195_CR112","unstructured":"Stahl, R. Eculizumab experience in HUS. Presented at the 2011 American Society of Nephrology Kidney Week."},{"key":"BFnrneph2012195_CR113","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2012)."},{"issue":"Suppl. 2","key":"BFnrneph2012195_CR114","first-page":"ii373","volume":"27","author":"J Kielstein","year":"2012","unstructured":"Kielstein, J. et al. Best supportive care and therapeutic plasma exchange [abstract SAP179]. Nephrol. Dial. Transplant. 27 (Suppl. 2), ii373\u2013ii374 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012195_CR115","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMc0809959","volume":"360","author":"RA Gruppo","year":"2009","unstructured":"Gruppo, R. A. & Rother, R. P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 544\u2013546 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012195_CR116","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1053\/j.ajkd.2011.11.027","volume":"59","author":"G Ariceta","year":"2012","unstructured":"Ariceta, G., Arrizabalaga, B., Aguirre, M., Morteruel, E. & Lopez-Trascasa, M. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am. J. Kidney Dis. 59, 707\u2013710 (2012).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012195_CR117","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJMc0808527","volume":"360","author":"J N\u00fcrnberger","year":"2009","unstructured":"N\u00fcrnberger, J. et al. Eculizumab for atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 542\u2013544 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012195_CR118","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1016\/j.transproceed.2010.09.125","volume":"42","author":"V Ch\u00e2telet","year":"2010","unstructured":"Ch\u00e2telet, V. et al. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant. Proc. 42, 4353\u20134355 (2010).","journal-title":"Transplant. Proc."},{"key":"BFnrneph2012195_CR119","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1056\/NEJMc1001060","volume":"362","author":"LB Zimmerhackl","year":"2010","unstructured":"Zimmerhackl, L. B. et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 362, 1746\u20131748 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012195_CR120","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00467-011-1879-9","volume":"26","author":"M Weitz","year":"2011","unstructured":"Weitz, M., Amon, O., Bassler, D., Koenigsrainer, A. & Nadalin, S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr. Nephrol. 26, 1325\u20131329 (2011).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012195_CR121","doi-asserted-by":"publisher","first-page":"197A","DOI":"10.1681\/ASN.2010121293","volume":"22","author":"C Licht","year":"2011","unstructured":"Licht, C. et al. Ph II study of eculizumab (ECU) in patients (PTS) with atypical hemolytic uremic syndrome (aHUS) receiving chronic plasma exchange\/infusion (PE\/PI) [abstract TH-PO366]. J. Am. Soc. Nephrol. 22, 197A (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012195_CR122","doi-asserted-by":"publisher","first-page":"197A","DOI":"10.1681\/ASN.2010121293","volume":"22","author":"LA Greenbaum","year":"2011","unstructured":"Greenbaum, L. A. et al. Continued improvements in renal function with sustained eculizumab (ECU) in patients (PTS) with atypical hemolytic uremic syndrome (aHUS) resistant to plasma exchange\/infusion (PE\/PI) [abstract TH-PO367]. J. Am. Soc. Nephrol. 22, 197A (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012195_CR123","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.molimm.2011.04.014","volume":"48","author":"TM Woodruff","year":"2011","unstructured":"Woodruff, T. M., Nandakumar, K. S. & Tedesco, F. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 48, 1631\u20131642 (2011).","journal-title":"Mol. Immunol."},{"key":"BFnrneph2012195_CR124","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1442-9071.2011.02581.x","volume":"40","author":"R Troutbeck","year":"2012","unstructured":"Troutbeck, R., Al-Qureshi, S. & Guymer, R. H. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin. Experiment. Ophthalmol. 40, 18\u201326 (2012).","journal-title":"Clin. Experiment. Ophthalmol."},{"key":"BFnrneph2012195_CR125","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","volume":"113","author":"AM Risitano","year":"2009","unstructured":"Risitano, A. M. et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 113, 4094\u20134100 (2009).","journal-title":"Blood"},{"key":"BFnrneph2012195_CR126","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.semnephrol.2010.06.006","volume":"30","author":"M Noris","year":"2010","unstructured":"Noris, M. & Remuzzi, G. Genetics and genetic testing in hemolytic uremic syndrome\/thrombotic thrombocytopenic purpura. Semin. Nephrol. 30, 395\u2013408 (2010).","journal-title":"Semin. Nephrol."},{"key":"BFnrneph2012195_CR127","doi-asserted-by":"publisher","first-page":"e1001013","DOI":"10.1371\/journal.pmed.1001013","volume":"8","author":"JE Salmon","year":"2011","unstructured":"Salmon, J. E. et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 8, e1001013 (2011).","journal-title":"PLoS Med."},{"key":"BFnrneph2012195_CR128","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","volume":"8","author":"M Le Quintrec","year":"2008","unstructured":"Le Quintrec, M. et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am. J. Transplant. 8, 1694\u20131701 (2008).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph2012195_CR129","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1056\/NEJMc0910965","volume":"362","author":"BE Lonze","year":"2010","unstructured":"Lonze, B. E., Singer, A. L. & Montgomery, R. A. Eculizumab and renal transplantation in a patient with CAPS. N. Engl. J. Med. 362, 1744\u20131745 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012195_CR130","first-page":"II274","volume":"110","author":"HL Lazar","year":"2004","unstructured":"Lazar, H. L. et al. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 110, II274\u2013II279 (2004).","journal-title":"Circulation"},{"key":"BFnrneph2012195_CR131","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.jtcvs.2007.12.062","volume":"136","author":"L Testa","year":"2008","unstructured":"Testa, L. et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J. Thorac. Cardiovasc. Surg. 136, 884\u2013893 (2008).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"BFnrneph2012195_CR132","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/rheumatology\/kem222","volume":"46","author":"CE Vergunst","year":"2007","unstructured":"Vergunst, C. E. et al. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford) 46, 1773\u20131778 (2007).","journal-title":"Rheumatology (Oxford)"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.195","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T17:16:26Z","timestamp":1687713386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2012.195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,18]]},"references-count":132,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["BFnrneph2012195"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2012.195","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,18]]}}}